<DOC>
	<DOCNO>NCT00299130</DOCNO>
	<brief_summary>This study evaluate efficacy safety rituximab patient active rheumatoid arthritis ( RA ) .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Rituximab Combination With Methotrexate Compared Methotrexate Alone Patients With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Inclusion criterion : Adult patient 1880 year age . Rheumatoid arthritis ( RA ) ≥ 6 month , diagnose accord revised 1987 American College Rheumatology ( ACR ) criterion classification rheumatoid arthritis . Receiving outpatient treatment RA . Swollen joint count ( SJC ) ≥ 8 ( 66 joint count ) , tender joint count ( TJC ) ≥ 8 ( 68 joint count ) screen baseline . At screening , either Creactive protein ( CRP ) ≥ 0.6 mg/dL ( 6 mg/L ) , Erythrocyte sedimentation rate ( ESR ) ≥ 28 mm/hour . Inadequate response methotrexate , receive tolerate dose 1025 mg/week ≥ 12 week . Exclusion criterion : Rheumatic autoimmune disease RA , significant systemic involvement secondary RA . Inflammatory joint disease RA , systemic autoimmune disorder . Diagnosis juvenile rheumatoid arthritis , RA age 16 . Surgery within 12 week study plan within 24 week randomization . Previous treatment approve investigational biological agent RA , antialpha4integrin antibody costimulation modulator , celldepleting therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>RA</keyword>
	<keyword>Rituxan</keyword>
	<keyword>SERENE</keyword>
</DOC>